Sensitivity analyses showing net monetary benefit for moderate, severe and total exacerbations
| Analysis method | A | B | C | D |
| Exacerbation | ||||
| Moderate | 1051.17 (621.34–1509.39) | 724.90 (251.26–1220.27) | 855.02 (433.42–1261.45) | 1166.22 (675.48–1663.27) |
| Severe | 1173.83 (563.49–1769.42) | 839.36 (195.49–1451.85) | 923.81 (392.95–1426.40) | 1107.01 (454.97–1748.75) |
| All | 2031.77 (1353.49–2748.34) | 1700.68 (990.78–2441.65) | 1523.32 (941.44–2068.36) | 2094.77 (1361.48–2852.22) |
Data are mean (95%CI). All monetary values quoted in AUD. A: Winsorised costs; B: antimicrobial resistance at twice upper bound cost per course; C: utility decrement experienced over 8 weeks, and societal willingness to pay per quality-adjusted life-year of AUD 64 000; D: exclusion of censored observations.